BidaskClub Upgrades Minerva Neurosciences (NERV) to Hold
BidaskClub upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a sell rating to a hold rating in a report issued on Tuesday morning.
Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Minerva Neurosciences from a buy rating to a hold rating in a report on Thursday, October 5th. ValuEngine lowered Minerva Neurosciences from a sell rating to a strong sell rating in a research note on Sunday, December 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $13.94.
Minerva Neurosciences (NASDAQ NERV) opened at $6.80 on Tuesday. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $11.20. The company has a market capitalization of $273.21, a price-to-earnings ratio of -6.13 and a beta of 1.53.
In related news, CFO Geoff Race sold 5,829 shares of Minerva Neurosciences stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total transaction of $33,749.91. Following the completion of the sale, the chief financial officer now owns 197,698 shares of the company’s stock, valued at $1,144,671.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 12,590 shares of company stock valued at $73,073 in the last three months. 21.60% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its stake in Minerva Neurosciences by 35.9% during the second quarter. Rhumbline Advisers now owns 27,082 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 7,150 shares during the period. Nationwide Fund Advisors boosted its stake in Minerva Neurosciences by 861.1% during the third quarter. Nationwide Fund Advisors now owns 124,990 shares of the biopharmaceutical company’s stock valued at $950,000 after buying an additional 111,985 shares during the period. Vanguard Group Inc. boosted its stake in Minerva Neurosciences by 14.4% during the second quarter. Vanguard Group Inc. now owns 1,074,239 shares of the biopharmaceutical company’s stock valued at $9,507,000 after buying an additional 134,942 shares during the period. EcoR1 Capital LLC bought a new stake in Minerva Neurosciences during the second quarter valued at $1,981,000. Finally, Laurion Capital Management LP bought a new stake in Minerva Neurosciences during the second quarter valued at $326,000. 73.68% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Upgrades Minerva Neurosciences (NERV) to Hold” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://theolympiareport.com/2018/01/20/bidaskclub-upgrades-minerva-neurosciences-nerv-to-hold.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.